$14.30
+0.42 (+3.03%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BVS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 3 observational · 5 with posted results
Held by 9 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, +4 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee OsteoarthritisNCT05100225Efficacy - Change from pretreatment baseline in the WOMAC pain subscaleRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Biological: PTP-001 · Other: Placebo control | Osteoarthritis, Knee | 210 | 2022-10-31 | 2022-07-19 |
| OSTEOAMP Lumbar Fusion Intra-Patient Controlled StudyNCT05405374Fusion StatusRandomized · Open-label · Treatment | Not applicable | Unknown status | Other: OSTEOAMP · Device: Infuse | Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease | 101 | Oct 2024 | 2023-08-28 |
| Study of StimRouter for Chronic Knee OA PainNCT05644639observationalKnee Pain | — | Completed | Device: StimRouter Neuromodulation System | Osteoarthritis, Knee | 13 | 2023-10-01actual | 2024-06-26 |
| Safety Study of PTP-001 for Treating Knee OsteoarthritisNCT04632966Incidence of local and systemic treatment emergent adverse events (AEs) and incidence of abnormal laboratory and immunogenicity panelsNon-randomized · Open-label · Treatment | Phase 1 | Unknown status | Biological: Biological: PTP-001 | Knee Osteoarthritis | 20 | Sep 2022 | 2021-12-22 |
| Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at RiskNCT03382483observationalAdjunctive treatment with low intensity pulsed ultrasound therapy mitigates the risk of fracture non-union in patients at risk | — | Completed | Device: Low intensity pulsed ultrasound | Mitigation of Fracture Non-union in Patients at Risk | 12,387 | 2020-05-26actual | 2025-10-28 |
| A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®NCT02225444observationalPosterolateral fusion evaluation as determined by physician's assessment | — | Completed | Other: OsteoAMP | Spondylolisthesis, Scoliosis, Intervertebral Disc Disease | 42 | 2019-06-24actual | 2020-11-05 |
| Prospective Single Center Open Label Study of Shoulder OA PainNCT02610504Shoulder pain on movement (SPOM) 0-100mm VASOpen-label · TreatmentStudy Protocol ↗ | Not applicable | Completed | Device: Durolane | Osteoarthritis | 41 | 2017-05-23actual | 2021-02-16 |
| 26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the AnkleNCT02627859AOS pain subscale scoreOpen-label · Treatment | Phase 4 | Unknown status | Device: Durolane SJ | Osteoarthritis | 37 | Aug 2016actual | 2016-09-21 |
| Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OANCT02110238results2016-06-23WOMAC VAS (0:None -100:Extreme) Pain Subscale Score Change From BaselineRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Supartz, Euflexxa | Osteoarthritis | 421 | Nov 2014actual | 2021-03-09 |
| Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the KneeNCT01543737Patients assessment of WOMAC A1 pain when walkingRandomized · Double-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: post transfer of company ownership from Smith \& Nephew to Bioventus LLC | Device: 3ml hyaluronic acid (DUROLANE), 2ml hyaluronic acid, (HYALGAN) | Knee Osteoarthritis | 290 | Feb 2014actual | 2016-02-12 |
| Trial to Evaluate UltraSound in the Treatment of Tibial FracturesNCT00667849results2015-12-08Change From Baseline in the SF-36 Physical Component Summary (PCS) Score of the Short Form-36 (SF-36)Randomized · Quadruple-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Study was terminated due to futility | Device: Exogen 4000+, Sham | Tibial Fractures | 501 | Dec 2012actual | 2015-12-08 |
| Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar SurgeryNCT00744861results2021-04-02Number of Participants With Posterolateral Fusion Success at the Treated LevelRandomized · Quadruple-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Terminated following interim analysis | Device: Exospine sham, Exospine, Exogen 4000+, Exogen 4000+ sham | Lumbar Degenerative Disc Disease | 328 | May 2012actual | 2021-04-02 |
| Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis PainNCT01295580results2021-04-09WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From BaselineRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: ARTZ, DUROLANE | Knee Osteoarthritis | 349 | Aug 2011actual | 2021-04-09 |
| SUPARTZ Versus Placebo in Osteoarthritis of the ShoulderNCT00479687results2021-04-02Visual Analogue Scale (VAS: 0-100) for Pain on MovementRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: SUPARTZ®, Phosphate Buffered Saline | Osteoarthritis of the Shoulder | 300 | Oct 2009actual | 2021-04-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19